9,300 Shares in DaVita Inc. $DVA Purchased by Polianta Ltd

Polianta Ltd bought a new stake in DaVita Inc. (NYSE:DVA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,300 shares of the company’s stock, valued at approximately $2,069,000. DaVita comprises approximately 0.3% of Polianta Ltd’s investment portfolio, making the stock its 20th biggest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DVA. Invesco Ltd. lifted its stake in shares of DaVita by 2.0% during the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after buying an additional 32,358 shares during the period. Morgan Stanley grew its stake in DaVita by 5.1% in the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after acquiring an additional 71,156 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in DaVita by 114.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in DaVita by 5.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock valued at $176,037,000 after acquiring an additional 56,336 shares during the last quarter. Finally, LSV Asset Management lifted its stake in shares of DaVita by 1.1% during the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after purchasing an additional 9,739 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DVA has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research report on Wednesday. Raymond James Financial set a $220.00 target price on DaVita in a research report on Friday. Truist Financial lowered their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, UBS Group increased their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $221.75.

DaVita Stock Up 1.5%

DaVita stock opened at $183.39 on Friday. The firm has a fifty day moving average of $218.43 and a 200-day moving average of $176.53. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The firm has a market capitalization of $11.70 billion, a P/E ratio of 15.01, a PEG ratio of 0.61 and a beta of 0.88.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the previous year, the business posted $2.95 EPS. The business’s quarterly revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita Inc. will post 14.57 EPS for the current fiscal year.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.90% of the stock is owned by company insiders.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.